Simultaneous Analysis of Tyrosine Kinase Inhibitors in Human Blood Plasma with LC/MS/MS

Introduction

Cancer treatment in recent years employs drugs known as molecular targeted drugs that were developed to target molecules related to the growth, invasion, and metastasis of tumor cells in order to inhibit tumor cell growth. Lung cancer treatment employs tyrosine kinase inhibitors (TKIs), which target the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), and new molecular targeted drugs, referred to as second and third generation drugs, continue to be developed. This article introduces an example of simultaneous analysis of EGFR-TKIs, ALK-TKIs, and metabolites in human blood plasma for the purpose of research into pharmacokinetics using the triple quadrupole high performance liquid chromatograph mass spectrometer LCMS-8050.

April 3, 2017 GMT